GlassScriptPhysician profile
Brett Michael Grieb
NPI 1740714419
$1,368.35
in general payments reported to CMS, 2019-2025
31 companies · $569 in 2025
The $569 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $281 · 2024: $518 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351 · Education: $17.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.13 |
| Education | $17.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $193.90 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $107.75 | 2024-2025 | Enhertu, Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $103.28 | 2024-2025 | Opdualag, Opdivo |
| Celgene Corporation | $93.89 | 2023-2024 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $86.44 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $75.84 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Janssen Biotech, INC. | $74.01 | 2023-2025 | Talvey, Tecvayli, Darzalex |
| Genzyme Corporation | $66.82 | 2023-2025 | |
| Eisai INC. | $60.47 | 2024-2025 | |
| Genmab U.S., INC. | $54.66 | 2023-2025 | Epkinly |
| Abbvie INC. | $52.77 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.79 | 2025 | |
| Glaxosmithkline, LLC. | $30.58 | 2024 | Jemperli, Zejula |
| Daiichi Sankyo INC. | $30.44 | 2023-2024 | Vanflyta, Enhertu |
| Astellas Pharma US INC | $29.60 | 2024-2025 | Vyloy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $22.65 | 2024 | |
| Immunogen, INC. | $19.27 | 2023 | Elahere |
| Organon LLC | $18.97 | 2023 | Ontruzant |
| Jazz Pharmaceuticals INC. | $18.64 | 2023 | Zepzelca |
| Takeda Pharmaceuticals U.S.A., INC. | $18.54 | 2023 | Ninlaro |
| Cti Biopharma Corp. | $17.77 | 2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $17.25 | 2024 | |
| Stemline Therapeutics INC. | $17.07 | 2024 | Elzonris |
| Genentech USA, INC. | $16.05 | 2023 | Tecentriq, Alecensa |
| Agios Pharmaceuticals, INC. | $15.98 | 2025 | Pyrukynd |
| Lilly USA, LLC | $15.71 | 2023 | Retevmo, Jaypirca, Verzenio |
| Boston Scientific Corporation | $15.24 | 2025 | Spaceoar Vue System - 10ml |
| Adaptive Biotechnologies Corporation | $14.59 | 2025 | Clonoseq |
| Medtronic, INC. | $14.43 | 2024 | Osteocool Rf Ablation System |
| Kite Pharma, INC. | $14.02 | 2024 | Yescarta |
| Puma Biotechnology, INC. | $13.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Grieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.